SSI Diagnostica (Group SSDI) acquired InDevR, which provides new analytical technologies, including multiplexed approaches to enable accelerated development and manufacturing of vaccines and other biotherapeutics.
The addition strengthens SSID’s pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities, according to a company official, who adds that InDevR also brings expertise in influenza and mRNA vaccine QC testing.
SSI Diagnostica Group, which has two complementary portfolios with both Life Science and In Vitro Diagnostics, serves three main application areas: vaccine development, disease surveillance, and diagnostic testing.
Last year, SSID Group expanded its In Vitro Diagnostics offering through the acquisition of Gulf Coast Scientific, adding urea breath testing to its already existing testing portfolio for H. pylori. With the acquisition of InDevR, SSID Group now accelerates growth of the Life Science Solution segment, noted Christina Lindved, CEO of SSI Diagnostica Group.
“We are well-positioned to address emerging needs, helping our customers scale and future-proof their vaccine pipelines,” said Lindved.
“From our earliest discussions, it was clear that SSID Group was an excellent fit to advance what we have built and to provide comprehensive support for our global biopharma customers,” stated Kathy Rowlen, CEO of InDevR. “Becoming part of the company enables us to accelerate our impact so that we, together, can bring a powerful, integrated portfolio to the global vaccine and surveillance markets.”
The post Multiplexing Company InDevR Acquired by SSI Diagnostica Group appeared first on GEN – Genetic Engineering and Biotechnology News.
